Sign up
Pharma Capital

Botanix Pharmaceuticals attracts $15 million for unique acne product

Funds raised will be used to accelerate clinical development of its lead acne product.
a girl with an acne
Global acne prescription market was worth circa US$4.9 billion in 2016

Botanix Pharmaceuticals Ltd (ASX:BOT) has successfully completed an oversubscribed $15 million placement to institutional and sophisticated investors at $0.11 per share.

The funds raised will be used to accelerate clinical development of its lead acne product, BTX 1503, and progress other key pipeline products.

BTX 1503 uses a synthetic form of a widely studied natural product, cannabidiol.

Advanced clinical programs in acne and atopic dermatitis

Botanix’s primary use of funds is to advance BTX 1503 into a phase II acne clinical study.

The remaining funds will be utilised to develop BTX 1204 (atopic dermatitis), BTX 1308 (psoriasis) and explore further the commercial potential of its proprietary drug delivery system, Permetrex.

Significantly, Botanix recently completed a phase 1b study in patients with acne, which met all the designated endpoints.

READ: Botanix Pharmaceuticals’ shares ride higher following successful acne study

Botanix’s study was conducted at four of the leading acne investigative sites in Australia and enrolled 21 subjects with moderate to severe acne, with 18 subjects completing the study.

Top line data indicated that BTX 1503 is effective at reducing the number of inflammatory and non-inflammatory acne lesions after 4 weeks of treatment.

It is worth noting that the reduction is greater than any other FDA approved topical acne product, for which data is available after 4 weeks of treatment.

Targeting the multi-billion dollar prescription markets for acne

Botanix is targeting the multi-billion dollar prescription markets for acne (with no new products approved in the last 20 years) and atopic dermatitis.

In 2016, the global acne prescription market was worth circa US$4.9 billion, with the potential to grow to circa US$7.3 billion by 2025.



Register here to be notified of future BOT Company articles
View full BOT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.